Dr. Jacobe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-2400Fax+1 214-645-2405- Is this information wrong?
Education & Training
- University of Texas Southwestern Medical CenterResidency, Dermatology, 1997 - 2000
- Baylor College of MedicineInternship, Internal Medicine, 1996 - 1997
- Baylor College of MedicineClass of 1996
Certifications & Licensure
- TX State Medical License 1998 - 2026
- NC State Medical License 2000 - 2003
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Start of enrollment: 2004 Nov 01
- Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Start of enrollment: 2012 May 01
- Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository Start of enrollment: 2007 May 01
Publications & Presentations
PubMed
- Examining the Role of Estheticians in Skin Cancer Surveillance.Amanda M Walker, Adrienne Joseph, Victoria E Orfaly, Elizabeth Stoos, Allan Geller, Nelson, J., Bailey, E., Savory, S., Leachman, S., Jacobe, H.> ;Dermatology. 2024 Jan 1
- Patients with autoimmune skin diseases are at increased risk of adverse pregnancy outcomes.Heejo Keum, Bonnie Bermas, Shivani Patel, Heidi T Jacobe, Benjamin F Chong> ;American Journal of Obstetrics & Gynecology MFM. 2024 Jan 1
- 2 citationsPansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis.Xing, E., Ma, F., Wasikowski, R., Billi, A., Gharaee-Kermani, M., Fox, J., Dobry, C., Victory, A., Sarkar, M., Xing, X., Plazyo, O., Chen, H., Barber, G., Jacobe, H., ...> ;JCI Insight. 2023 Aug 22
- Join now to see all
Journal Articles
- An Evaluation of the Performance of Current Morphea Subtype ClassificationsHeidi Jacobe, MD, JAMA Dermatology
- A Cross-Sectional Comparison of Magnetic Resonance Imaging Findings and Clinical Assessment in Patients with MorpheaShauna Goldman, Heidi T Jacobe, JAMA Dermatology
Other
- Morphea: Current ConceptsHeidi Jacobe, MD, ScienceDirect
https://www.doximity.com/articles/844e913b-eeea-47ac-9b2b-29be6753aa98
UpToDate, Wolters Kluwer Health - 2012-01-20
Press Mentions
- Jeff Aronin Announces Matthew Gantz as CEO of Castle Creek BiosciencesMay 11th, 2021
- Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea in Adults and Children (MAC) CohortNovember 26th, 2020
- Role of Antibody Unclear in Scleroderma VariantAugust 10th, 2013
Professional Memberships
- Fellow
- Research Member
Hospital Affiliations
- University of Texas Southwestern Medical CenterDallas, Texas
- Children's Medical Center DallasDallas, Texas
- Parkland HealthDallas, Texas
- Dallas VA North Texas HCSDallas, Texas
- William P. Clements, Jr. University HospitalDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: